Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells

ABSTRACT Cytotoxic T cells substantially contribute to the control of intracellular pathogens such as human immunodeficiency virus type 1 (HIV-1). Here, we evaluated the immunopeptidome of Jurkat cells infected with the vaccine candidate MVA.HIVconsv, which delivers HIV-1 conserved antigenic regions by using modified vaccinia virus Ankara (MVA). We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify 6,358 unique peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were derived from the MVA vector and 7 were derived from the HIVconsv immunogen. Human vaccine recipients responded to the peptide sequences identified by LC-MS/MS. Peptides derived from the conserved HIV-1 regions were readily detected as early as 1.5 h after MVA.HIVconsv infection. Four of the seven conserved peptides were monitored between 0 and 3.5 h of infection by using quantitative mass spectrometry (Q-MS), and their abundance in HLA class I associations reflected levels of the whole HIVconsv protein in the cell. While immunopeptides delivered by the incoming MVA vector proteins could be detected, all early HIVconsv-derived immunopeptides were likely synthesized de novo. MVA.HIVconsv infection generally altered the composition of HLA class I-associated human (self) peptides, but these changes corresponded only partially to changes in the whole cell host protein abundance. IMPORTANCE The vast changes in cellular antigen presentation after infection of cells with a vectored vaccine, as shown here for MVA.HIVconsv, highlight the complexity of factors that need to be considered for efficient antigen delivery and presentation. Identification and quantitation of HLA class I-associated peptides by Q-MS will not only find broad application in T-cell epitope discovery but also inform vaccine design and allow evaluation of efficient epitope presentation using different delivery strategies.

[1]  A. McMichael,et al.  Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. , 2007, The Journal of general virology.

[2]  Todd M. Allen,et al.  Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection , 2003, AIDS (London).

[3]  T. Hanke,et al.  MVA as a vector for vaccines against HIV-1 , 2004, Expert review of vaccines.

[4]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[5]  M. Buchmeier,et al.  Cutting Edge: Neosynthesis Is Required for the Presentation of a T Cell Epitope from a Long-Lived Viral Protein1 , 2001, The Journal of Immunology.

[6]  A. Nicosia,et al.  Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques , 2012, AIDS.

[7]  Morten Nielsen,et al.  Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers , 2008, Bioinform..

[8]  T. Hanke,et al.  Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice , 2014, Clinical and Vaccine Immunology.

[9]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[10]  Felipe García,et al.  Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS , 2010, Journal of Virology.

[11]  R. Fåhraeus,et al.  Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation , 2011, Proceedings of the National Academy of Sciences.

[12]  T. Hanke.  Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines , 2014, Expert opinion on biological therapy.

[13]  James I Mullins,et al.  HIV-1 Group M Conserved Elements Vaccine , 2007, PLoS pathogens.

[14]  A. Goldberg,et al.  Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. , 1995, Journal of immunology.

[15]  R. Cortese,et al.  ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  J. Mullins,et al.  Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design , 2013, PloS one.

[17]  J. Yewdell,et al.  Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.

[18]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[19]  J. Mullins,et al.  Preinfection Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T Lymphocytes Failed To Prevent HIV Type 1 Infection from Strains Genetically Unrelated to Viruses in Long-Term Exposed Partners , 2009, Journal of Virology.

[20]  A. McMichael,et al.  Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges , 2011, PLoS pathogens.

[21]  K. Früh,et al.  Cowpox Virus Evades CTL Recognition and Inhibits the Intracellular Transport of MHC Class I Molecules1 , 2007, The Journal of Immunology.

[22]  R. Kennedy,et al.  Cutting Edge: Class I Presentation of Host Peptides Following HIV Infection1 , 2003, The Journal of Immunology.

[23]  M. Mannie,et al.  Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T‐cell priming, and peptide association with MHC class II , 2009, Immunology.

[24]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[25]  B. Coupar,et al.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen , 1988, The Journal of experimental medicine.

[26]  Wilfried Bardet,et al.  HLA class I molecules reflect an altered host proteome after influenza virus infection. , 2010, Human immunology.

[27]  D. Busch,et al.  Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination , 2007, The Journal of experimental medicine.

[28]  Todd M. Allen,et al.  Hitting HIV where it hurts: an alternative approach to HIV vaccine design. , 2006, Trends in immunology.

[29]  Andrew L. Ferguson,et al.  Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. , 2013, Immunity.

[30]  Arie Admon,et al.  The nature and extent of contributions by defective ribosome products to the HLA peptidome , 2014, Proceedings of the National Academy of Sciences.

[31]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[32]  Bin Ma,et al.  PEAKS DB: De Novo Sequencing Assisted Database Search for Sensitive and Accurate Peptide Identification* , 2011, Molecular & Cellular Proteomics.

[33]  B. Walker,et al.  The T-cell response to HIV. , 2012, Cold Spring Harbor perspectives in medicine.

[34]  H. Stickl,et al.  Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA , 1975, Infection.

[35]  B. Moss,et al.  Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.

[36]  R. Randall,et al.  Expression and purification of nonglycosylated SIV proteins, and their use in induction and detection of SIV-specific immune responses. , 1994, AIDS research and human retroviruses.

[37]  H Robert Bergen,et al.  Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. , 2009, Vaccine.

[38]  Todd M. Allen,et al.  HIV evolution: CTL escape mutation and reversion after transmission , 2004, Nature Medicine.

[39]  H. Grey,et al.  Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. , 1984, Journal of immunology.

[40]  Edward C. Holmes,et al.  Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[41]  Volker Brass,et al.  Identification of Naturally Processed Hepatitis C Virus-Derived Major Histocompatibility Complex Class I Ligands , 2012, PloS one.

[42]  Bette Korber,et al.  Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine , 2007, PloS one.

[43]  H. McShane,et al.  Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis , 2011, PloS one.

[44]  B. Charleston,et al.  Modified Vaccinia Virus Ankara-Based Vaccine Vectors Induce Apoptosis in Dendritic Cells Draining from the Skin via both the Extrinsic and Intrinsic Caspase Pathways, Preventing Efficient Antigen Presentation , 2012, Journal of Virology.

[45]  J. Yewdell,et al.  Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands , 2011, Cellular and Molecular Life Sciences.

[46]  A Sette,et al.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.

[47]  B. Moss,et al.  Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. , 1996, Vaccine.

[48]  B. Ensoli,et al.  Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. , 2008, Vaccine.

[49]  Zhongde Wang,et al.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines , 2009, Vaccine.

[50]  E. Caron,et al.  The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.

[51]  A. Nicosia,et al.  Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine , 2012, Journal of Virology.

[52]  R. Welsh,et al.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens , 2002, Nature Immunology.

[53]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[54]  G. Renukaradhya,et al.  Inhibition of CD1d1‐mediated antigen presentation by the vaccinia virus B1R and H5R molecules , 2006, European journal of immunology.

[55]  Lucy Dorrell,et al.  Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  K. Rock,et al.  Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides , 2012, Proceedings of the National Academy of Sciences.

[57]  J. Yewdell,et al.  Distinct Pathways Generate Peptides from Defective Ribosomal Products for CD8+ T Cell Immunosurveillance , 2011, The Journal of Immunology.

[58]  N. Shastri,et al.  The Synthesis of Truncated Polypeptides for Immune Surveillance and Viral Evasion , 2010, PloS one.

[59]  Dennis R. Burton,et al.  Toward an AIDS Vaccine , 2008, Science.

[60]  Albert J R Heck,et al.  Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD) , 2014, Proceedings of the National Academy of Sciences.

[61]  J. Yewdell,et al.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.

[62]  Anthony W. Purcell,et al.  Kinetics of Antigen Expression and Epitope Presentation during Virus Infection , 2013, PLoS pathogens.

[63]  S. Rowland-Jones,et al.  Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine , 2006, Journal of Virology.

[64]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[65]  A. Nicosia,et al.  Long peptides induce polyfunctional T cells against conserved regions of HIV‐1 with superior breadth to single‐gene vaccines in macaques , 2010, European journal of immunology.

[66]  M. Feinberg,et al.  Dendritic Cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo , 2008, BMC Immunology.

[67]  Sébastien Lemieux,et al.  The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.